Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound.
Two hundred forty pyridazinamine derivatives were tested for the ability to stabilize the antigenicity and infectivity of oral poliovirus vaccine subjected to 45 degrees C for 2 h. Seven compounds stabilized the antigenicity of all three vaccine strains and neutralized the viral particles in a way that is reversible by dilution. Of these, R 77975 (pirodavir) was selected for vaccine potency tests. Sabin type 2 and type 3 strains were subjected to 4, 25, 42, and 45 degrees C for 1 week in the presence and absence of R 77975. Although R 77975 particularly stabilized the infectivity of the most thermolabile vaccine strain (Sabin type 3), the protection did not exceed that of 1 M MgCl2. When virus was inactivated in the absence of R 77975, the native or N antigenicity changed in H antigenicity. However, in the presence of the capsid-binding compound, N antigenicity was preserved in particles that had lost infectivity.
Andries
K
K
Department of Virology, Janssen Research Foundation, Beerse, Belgium.
Rombaut
B
B
Dewindt
B
B
Boeyé
A
A
D000998:Antiviral Agents / Q000494:pharmacology*; D004355:Drug Stability; D006367:HeLa Cells; D006801:Humans; D010880:Piperidines / Q000494:pharmacology*; D017955:Poliovirus / Q000254:growth & development; D011055:Poliovirus Vaccine, Oral / Q000276:immunology* / Q000494:pharmacology*; D011724:Pyridazines / Q000737:chemistry / Q000494:pharmacology*
D000998:Antiviral Agents; D010880:Piperidines; D011055:Poliovirus Vaccine, Oral; D011724:Pyridazines; C062482:pyridazine; C074589:pirodavir